Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 13 de 13
Filtrar
1.
BMC Pulm Med ; 24(1): 373, 2024 Jul 31.
Artículo en Inglés | MEDLINE | ID: mdl-39085811

RESUMEN

BACKGROUND: The six-minute walk test (6MWT) is widely used to assess functional capacity and prognosis in patients with idiopathic pulmonary fibrosis (IPF). However, studies on oxygen saturation recovery after the 6MWT in patients with IPF are rare. In our study, we investigated the relationship between oxygen saturation recovery time and dyspnea, fatigue, quality of life, prognostic markers and pulmonary hypertension (PH). METHODS: In this cross-sectional study, IPF patients diagnosed according to current guidelines and followed up in our Interstitial Lung Disease Outpatient Clinic between 2021 and 2022 were included. Demographics, data from spirometry, diffusion capacity measurement, arterial blood gas analysis, transthoracic echocardiography and the 6MWT were recorded. The oxygen saturation recovery time, distance saturation product (DSP), gender-age-physiology (GAP) index and composite physiological index (CPI) scores were calculated. Dyspnea severity was assessed by the modified Medical Research Council (mMRC) and Dyspnoea-12 (D-12) scales, fatigue severity by the Multidimensional Fatigue Inventory (MFI-20) and quality of life by the St George's Respiratory Questionnaire (SGRQ). RESULTS: Fifty IPF patients (34 men, 16 women, age: 66.8 ± 7.3 years) were included in the study. The mean FVC was 77.8 ± 19.3%, the DLCO was 52.9 ± 17.1%, the 6-minute walk distance (6MWD) was 385.7 ± 90.6 m, the GAP index was 3.5 ± 1.5, and the CPI was 43.7 ± 14.1. Oxygen saturation after the 6MWT reached pretest values at an average of 135.6 ± 73.5 s. The oxygen saturation recovery time was longer in patients with higher GAP index scores (Rs = 0.870, p < 0.001), CPI scores (Rs = 0.906, p < 0.001), desaturation (Rs = 0.801, p < 0.001), FVC%/DLCO% (Rs = 0.432, p = 0.002), sPAP (Rs = 0.492, p = 0.001), TRV (Rs = 0.504, p = 0.001), mMRC (Rs = 0.913, p < 0.001), MFI-20 (Rs = 0.944, p < 0.001), D-12 scale (Rs = 0.915, p < 0.001) and SGRQ scores (Rs = 0.927, p < 0.001); lower FVC (%) (Rs=-0.627, p < 0.001), DLCO (%) (Rs=-0.892, p < 0.001), PaO2 (Rs=-0.779, p < 0.001), DSP (Rs=-0.835, p < 0.001), and 6MWD (Rs=-0.763, p < 0.001). A total of twenty patients (40%) exhibited an increased risk of PH. According to our multiple regression analysis, oxygen saturation recovery time was independently associated with the GAP index (p = 0.036), the lowest oxygen saturation occurring during the 6MWT (p = 0.011) and the SGRQ score (p < 0.001). CONCLUSIONS: Our results showed that oxygen saturation recovery time is associated with dyspnea, fatigue, quality of life, increased risk of PH and prognostic markers in IPF. Therefore, we recommend continuous measurement of oxygen saturation after 6MWT until pretest values are reached.


Asunto(s)
Disnea , Fibrosis Pulmonar Idiopática , Saturación de Oxígeno , Calidad de Vida , Prueba de Paso , Humanos , Femenino , Fibrosis Pulmonar Idiopática/fisiopatología , Fibrosis Pulmonar Idiopática/sangre , Masculino , Anciano , Persona de Mediana Edad , Estudios Transversales , Disnea/fisiopatología , Disnea/etiología , Fatiga/fisiopatología , Fatiga/etiología , Hipertensión Pulmonar/fisiopatología , Pronóstico , Tolerancia al Ejercicio/fisiología , Análisis de los Gases de la Sangre
2.
Thorac Res Pract ; 2023 Nov 28.
Artículo en Inglés | MEDLINE | ID: mdl-38015164

RESUMEN

Sleep-related breathing disorders (SRBD) comprise obstructive sleep apnea (OSA), central sleep apnea (CSA), obesity-hypoventilation syndrome (OHS), as well as isolated sleep-related hypoxemia (ISRH), according to the recent International Classification of Sleep Disorders 3. During the last decades, there have been cumulative research reports indicating an association between the SRBD and increased cardiometabolic illness and death, as well as decreased quality of life. Notwithstanding, the results have been inconclusive, and the evidence level was not high regarding the effect of treatment for the SRBD on adverse outcomes. In the current work, we aim to give a comprehensive review of the clinical trials published from January 2022 to August 31, 2023. We highlight the heterogeneity of cardiometabolic disorders among adults with SRBD and particularly emphasize OSA management, drug therapy for OSA, positive airway pressure (PAP) therapy and cardiovascular outcomes, other effects of PAP in pregnancy and neurocognitive function, as well as the effects of surgical treatment and oral appliances. We also underline future directions in OSA management, telemonitoring, and druginduced sleep endoscopy in managing the SRBD, especially OSA. We ascertain that more studies are needed within the CSA, OHS, and ISRH research fields.

3.
Muscle Nerve ; 63(5): 683-689, 2021 05.
Artículo en Inglés | MEDLINE | ID: mdl-33576026

RESUMEN

INTRODUCTION: In this study, we aimed to evaluate diaphragmatic dysfunction (DD) by using a practical approach in patients with amyotrophic lateral sclerosis (ALS) at the first visit to a chest diseases outpatient clinic. METHODS: Patients with ALS seen in our outpatient clinic for the past 5 y and followed up for at least 1 y, were retrospectively evaluated. Having at least one of the following three criteria was accepted as DD: (a) paradoxical abdominal movement (PAM), (b) sitting-supine forced vital capacity (FVC) difference ≥ 20%, (c) sitting-supine arterial oxygen saturation measured by pulse oximetry (SpO2 ) difference ≥ 4%. Respiratory symptoms, arterial blood gas analysis, sleep studies, noninvasive mechanical ventilation use, and mortality were recorded. RESULTS: Five-hundred patients with ALS were included (female/male: 220/280, age: 58.9 ± 11.3 y). Of the patients, 22.8% had daytime hypercapnia. DD was observed in 55% of the patients (PAM in 112, sitting-supine FVC difference ≥ 20% in 50, and sitting-supine SpO2 difference ≥ 4% in 113 patients). Of the patients with DD, 31.6% (n = 87) had no respiratory symptoms, 46.4% had FVC > 70% and 33.5% had FVC <50%. Nocturnal hypoxemia (sleep time spent with SpO2 < 90% ≥30%) was present in 59.7%, and all patients with nocturnal hypoxemia had DD. Obstructive sleep apnea (8 severe, 14 moderate, 39 mild) was detected in 55% of the patients with polysomnography (n = 61) or polygraphy (n = 50). During follow-up, 52.2% of the patients died. Mean survival time was shorter in patients with DD (P < .001). CONCLUSION: Paradoxical abdomimal movement (PAM), sitting-supine SpO2 difference ≥ 4% and sitting-supine FVC difference ≥ 20% are indicators of DD, which should be routinely evaluated at every outpatient visit.


Asunto(s)
Esclerosis Amiotrófica Lateral/fisiopatología , Diafragma/fisiopatología , Hipercapnia/fisiopatología , Anciano , Instituciones de Atención Ambulatoria , Femenino , Humanos , Masculino , Persona de Mediana Edad , Pruebas de Función Respiratoria , Estudios Retrospectivos , Capacidad Vital
4.
Int J Chron Obstruct Pulmon Dis ; 13: 3367-3372, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-30410323

RESUMEN

BACKGROUND: Endothelial cell specific molecule-1, also called as endocan, is a dermatan sulfate proteoglycan, which is expressed by endothelial cells in alveolar walls of the lung and kidney. High endocan levels are found associated with endothelial dysfunction and inflammation. We hypothesize that endocan level is also high in COPD due to systemic inflammation and endothelial dysfunction. We aimed to investigate the expression of endocan in patients with stable COPD. MATERIAL AND METHODS: The study included patients with COPD and control subjects. COPD patients were classified according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017 criteria. Demographics, body mass index, smoking history, and comorbidities were recorded. Endocan levels of COPD patients and controls were compared. RESULTS: Totally, 88 subjects (47 stable COPD patients, 41 controls) were evaluated. Endocan levels were significantly higher in COPD patients than control group (860.1±259.8 vs 647.3±316.9 pg/mL, P=0.001). There was no relationship between GOLD COPD categories and endocan levels. Also endocan levels were similar between COPD patients with or without hypoxemia. CONCLUSION: Serum endocan level was significantly higher in patients with stable COPD. Further studies should be performed to better understand the relationship between endocan and COPD.


Asunto(s)
Células Epiteliales Alveolares/inmunología , Proteínas de Neoplasias , Proteoglicanos , Enfermedad Pulmonar Obstructiva Crónica , Adulto , Anciano , Correlación de Datos , Femenino , Humanos , Inflamación/inmunología , Masculino , Persona de Mediana Edad , Proteínas de Neoplasias/análisis , Proteínas de Neoplasias/inmunología , Gravedad del Paciente , Proteoglicanos/análisis , Proteoglicanos/inmunología , Enfermedad Pulmonar Obstructiva Crónica/diagnóstico , Enfermedad Pulmonar Obstructiva Crónica/inmunología
5.
Tuberk Toraks ; 66(4): 304-311, 2018 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-30683025

RESUMEN

INTRODUCTION: Obstructive sleep apnea (OSA) syndrome is closely associated with cardiovascular and metabolic disorders. Recent studies reported that osteoarthritis (OA) is associated with cardiovascular disease as well as inflammation defined as "metabolic disorder". Due to the strong association of metabolic disorders with both OA and OSA, we aimed to investigate the association between severity of OSA and osteoarthritis grade based on X-Ray. MATERIALS AND METHODS: Patients who underwent polysomnography due to suspicion of OSA were recruited in a cross-sectional study. Included patients were grouped according to apnea-hypopnea index (AHI) as mild (AHI between 5 and 14.9), moderately (AHI between 15 and 29.9), and severe OSA (AHI ≥ 30). Patients with AHI p< 5 served as the control group. Kellgren-Lawrence scoring system was used to express OA severity, which was graded as Grade 0, 1, 2, 3 and 4. RESULT: One hundred twenty patients were enrolled into the study. Mean age was 52.4 ± 11.5 years and 56% (68/120) of the patients were male. A strong correlation was present between severity of OSA and severity of OA. Among those with Grade 4 OA group (33 patients), all patients had severe OSA and this association was independent from body-mass index. In the Grade 1 OA group, none of the patients had severe OSA (p< 0.05). A positive correlation was also seen between severity of OSA, OA and hs-CRP. CONCLUSIONS: There is a strong association between OSA and OA. OSA might be a novel risk factor for the development OA. Further studies should evaluate the effect of OSA treatment on OA.


Asunto(s)
Índice de Masa Corporal , Osteoartritis/etiología , Medición de Riesgo , Apnea Obstructiva del Sueño/complicaciones , Estudios Transversales , Femenino , Humanos , Incidencia , Masculino , Persona de Mediana Edad , Osteoartritis/epidemiología , Polisomnografía , Factores de Riesgo , Apnea Obstructiva del Sueño/diagnóstico , Turquía/epidemiología , Adulto Joven
6.
Balkan Med J ; 34(1): 41-46, 2017 01.
Artículo en Inglés | MEDLINE | ID: mdl-28251022

RESUMEN

BACKGROUND: As obesity increases, the frequency of obstructive sleep apnea and obesity hypoventilation syndrome increases also. However, obesity hypoventilation syndrome frequency is not known, as capnography and arterial blood gas analysis are not routinely performed in sleep laboratories. AIMS: To investigate the frequency and predictors of obesity hypoventilation syndrome in obese subjects. STUDY DESIGN: Retrospective clinical study. METHODS: Obese subjects who had arterial blood gas analysis admitted to the sleep laboratory and polysomnography were retrospectively analyzed. Subjects with restrictive (except obesity) and obstructive pulmonary pathologies were excluded. Demographics, Epworth-Sleepiness-Scale scores, polysomnographic data, arterial blood gas analysis, and spirometric measurements were recorded. RESULTS: Of the 419 subjects, 45.1% had obesity hypoventilation syndrome. Apnea hypopnea index (p<0.001), oxygen desaturation index (p<0.001) and sleep time with SpO2<90% (p<0.001) were statistically higher in subjects with obesity hypoventilation syndrome compared to subjects with eucapnic obstructive sleep apnea. The nocturnal mean SpO2 (p<0.001) and lowest SpO2 (p<0.001) were also statistically lower in subjects with obesity hypoventilation syndrome. Logistic regression analysis showed that the lowest SpO2, oxygen desaturation index, apnea hypopnea index and sleep time with SpO2 <90% were related factors for obesity hypoventilation syndrome. CONCLUSION: Obesity hypoventilation syndrome should be considered when oxygen desaturation index, apnea hypopnea index and sleep time with SpO2 <90% are high.


Asunto(s)
Análisis de los Gases de la Sangre/estadística & datos numéricos , Síndrome de Hipoventilación por Obesidad/complicaciones , Síndrome de Hipoventilación por Obesidad/diagnóstico , Apnea Obstructiva del Sueño/etiología , Adulto , Índice de Masa Corporal , Femenino , Humanos , Modelos Logísticos , Masculino , Persona de Mediana Edad , Síndrome de Hipoventilación por Obesidad/sangre , Estudios Retrospectivos , Estadísticas no Paramétricas
7.
Intern Med ; 55(13): 1783-6, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-27374684

RESUMEN

We herein report a patient case with familial amyloidotic polyneuropathy (FAP) who presented with vocal cord paralysis (VCP). A 60-year-old man with FAP (Gly89Gln) presented with hoarseness and snoring for the previous two years. A chest X-ray demonstrated cardiomegaly and bilateral diaphragmatic elevation. The findings of a restrictive pattern on spirometry and daytime hypercapnia were consistent with respiratory muscle weakness related to neuropathy [forced expiratory volume (FEV1): 38%, forced vital capacity (FVC): 39%, FEV1/FVC: 77, partial pressure of arterial oxygen (PaO2): 80 mmHg, partial pressure of carbon dioxide in arterial blood (PaCO2): 52 mmHg]. An ear-nose-throat examination showed VCP. Polysomnography revealed severe obstructive sleep apnea (OSA). FAP may cause OSA by VCP and hypercapnic respiratory failure by respiratory muscle weakness. Therefore, an ear-nose-throat examination, spirometry, arterial blood gases analysis and polysomnography are important for these patients.


Asunto(s)
Hipercapnia/etiología , Polineuropatías/complicaciones , Parálisis de los Pliegues Vocales/etiología , Análisis de los Gases de la Sangre , Humanos , Hipercapnia/sangre , Hipercapnia/fisiopatología , Masculino , Persona de Mediana Edad , Polineuropatías/fisiopatología , Pruebas de Función Respiratoria , Insuficiencia Respiratoria , Apnea Obstructiva del Sueño/etiología , Apnea Obstructiva del Sueño/fisiopatología , Parálisis de los Pliegues Vocales/fisiopatología
8.
Biomark Med ; 10(2): 177-84, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-26808694

RESUMEN

OBJECTIVE: To investigate the level of endothelial cell specific molecule-1 (endocan) in obstructive sleep apnea (OSA). METHODS: Study group included subjects with OSA. Control group included subjects who had no OSA on polysomnography and nonobese healthy subjects from population who had no OSA symptoms. Endocan levels of OSA and non-OSA subjects were compared. RESULTS: Totally 106 individuals (63 OSA, 43 non-OSA) were included. Endocan levels were higher in OSA subjects than controls (1.25 ± 0.4 ng/ml vs 0.93 ± 0.3 ng/ml, p < 0.001). Endocan levels were correlated with BMI (r = 0.456, p < 0.001) and daytime PaO2 (r = -0.266, p < 0.042). In linear regression analysis there was no factor related to endocan level. CONCLUSION: Serum endocan is significantly higher in OSA. Further studies should be performed to better understand the relationship between endocan and OSA.


Asunto(s)
Biomarcadores/sangre , Células Endoteliales/metabolismo , Proteínas de Neoplasias/sangre , Proteoglicanos/sangre , Apnea Obstructiva del Sueño/sangre , Adulto , Anciano , Índice de Masa Corporal , Femenino , Humanos , Hipercapnia/sangre , Hipoxia/sangre , Masculino , Persona de Mediana Edad , Polisomnografía , Estudios Prospectivos , Análisis de Regresión , Apnea Obstructiva del Sueño/epidemiología , Apnea Obstructiva del Sueño/metabolismo , Adulto Joven
9.
Sleep Breath ; 20(2): 495-500, 2016 May.
Artículo en Inglés | MEDLINE | ID: mdl-26047651

RESUMEN

PURPOSE: The STOP-BANG questionnaire (SBQ) has never been studied in the context of its ability to predict obesity hypoventilation syndrome (OHS). Our aim was to evaluate the predictive performance of the original and modified SBQs for OHS in obese subjects with obstructive sleep apnea (OSA). METHODS: Demographics, polysomnographic data, body mass index (BMI), Epworth Sleepiness Scale (ESS) scores, arterial blood gases, spirometric measurements, and SBQ scores were recorded. The modified SBQ was created by dividing BMI into ranges and adding the serum bicarbonate ranges. RESULTS: The study included 196 obese subjects, of whom 17 had normal polysomnography. Of the remaining subjects, 105 had pure OSA and 74 had OHS with OSA. Both the original and modified SBQs scores were higher for the OHS subjects than for those with pure OSA (p < 0.001). An original SBQ score of ≥6 gave a satisfactory discrimination for OHS diagnosis (sensitivity 71.6 %, specificity 59.1 %, positive predictive value (PPV) 55.2 %, and negative predictive value (NPV) 74.7 %). The diagnostic OR for an original SBQ score of ≥6 for predicting OHS was 3.7. The sensitivity and NPV were increased for the modified SBQ (sensitivity 89.2 %, specificity 47.6 %, PPV 54.6 %, NPV 86.2 %), and the OR was 7.5. Both the original and modified SBQ scores were moderately correlated with ESS, AHI, ODI, lowest SpO2, and sleep time spent with SpO2 <90 %. CONCLUSIONS: The modified SBQ can be used to screen for OHS in obese subjects.


Asunto(s)
Síndrome de Hipoventilación por Obesidad/diagnóstico , Obesidad/complicaciones , Apnea Obstructiva del Sueño/diagnóstico , Encuestas y Cuestionarios , Diagnóstico Diferencial , Humanos , Obesidad/diagnóstico , Polisomnografía , Valor Predictivo de las Pruebas , Sensibilidad y Especificidad , Estadística como Asunto
10.
Respir Care ; 60(5): 666-72, 2015 May.
Artículo en Inglés | MEDLINE | ID: mdl-25587164

RESUMEN

BACKGROUND: Arterial blood gas (ABG) analysis is not a routine test in sleep laboratories due to its invasive nature. Therefore, the diagnosis of obesity hypoventilation syndrome (OHS) is underestimated. We aimed to evaluate the differences in subjects with OHS and pure obstructive sleep apnea (OSA) and to determine clinical predictors of OHS in obese subjects. METHODS: Demographics, body mass index (BMI), Epworth Sleepiness Scale score, polysomnographic data, ABG, spirometric measurements, and serum bicarbonate levels were recorded. RESULTS: Of 152 obese subjects with OSA (79 females/73 males, mean age of 50.3 ± 10.6 y, BMI of 40.1 ± 5.6 kg/m(2), 51.9% with severe OSA), 42.1% (n = 64) had OHS. Subjects with OHS had higher BMI (P = .02), neck circumference (P < .001), waist circumference (P < .001), waist/hip ratio (P = .02), Epworth Sleepiness Scale scores (P = .036), ABG and serum bicarbonate levels (P < .001), apnea-hypopnea index (P = .01), oxygen desaturation index (P < .001), and total sleep time with S(pO2) < 90% (P < .001) compared with subjects with pure OSA (n = 88). They also had lower daytime PaO2 (P < .001), sleep efficiency (P = .032), mean S(pO2) (P < .001), and nadir S(pO2) (P < .001). Serum bicarbonate levels and nadir S(pO2) were the only independent predictive factors for OHS. A serum bicarbonate level of ≥ 27 mmol/L as the cutoff gives a satisfactory discrimination for the diagnosis of OHS (sensitivity of 76.6%, specificity of 74.6%, positive predictive value of 54.5%, negative predictive value of 88.9%). A nadir S(pO2) of < 80% as the cutoff gives a satisfactory discrimination for the diagnosis of OHS (sensitivity of 82.8%, specificity of 54.5%, positive predictive value of 56.9%, negative predictive value of 81.4%). When we used a serum bicarbonate level of ≥ 27 mmol/L and/or a nadir S(pO2) of < 80% as a screening measure, only 3 of 64 subjects with OHS were missed. CONCLUSIONS: Serum bicarbonate level and nadir saturation were independent predictive factors for the diagnosis of OHS.


Asunto(s)
Síndrome de Hipoventilación por Obesidad/etiología , Obesidad/complicaciones , Apnea Obstructiva del Sueño/etiología , Anciano , Bicarbonatos/sangre , Análisis de los Gases de la Sangre , Índice de Masa Corporal , Femenino , Humanos , Masculino , Persona de Mediana Edad , Obesidad/sangre , Síndrome de Hipoventilación por Obesidad/sangre , Polisomnografía , Valor Predictivo de las Pruebas , Factores de Riesgo , Sueño , Apnea Obstructiva del Sueño/sangre , Relación Cintura-Cadera
11.
Clin Respir J ; 9(1): 14-21, 2015 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-24405843

RESUMEN

INTRODUCTION: Increased obstructive sleep apnea (OSA) incidence has been reported in sarcoidosis. However, no research has been conducted to determine the relation between OSA and pulmonary parenchymal involvement in sarcoidosis. OBJECTIVES: We investigated OSA frequency and association between pulmonary parenchymal involvement and OSA in sarcoidosis. Additionally, relationship between lung functions and polysomnography data was assessed. METHODS: The study enrolled sarcoidosis subjects with or without pulmonary parenchymal involvement. Spirometry, diffusion capacity, 6-min walking test, arterial blood gases, chest X-ray, Epworth sleepiness scale (ESS) and polysomnography were performed. Subjects with body mass index (BMI) ≥30 or significant upper airway pathologies that might cause OSA were excluded. RESULTS: A total of 29 sarcoidosis subjects (15 with, 14 without parenchymal involvement) with mean age 43.8 ± 9.4 years were analyzed. Twenty-seven of them were female. BMI was 26.8 ± 4.2 kg/m(2) . Mean forced expiratory volume 1 s (FEV1 ) was 97.89% ± 20.21%, and forced vital capacity (FVC) was 102.86 ± 18.14%. ESS score was 4 ± 1.6. OSA was identified in 51.7% (n = 15) of subjects. Apnea-hypopnea index (AHI) was 16.16 ± 19/h and oxygen desaturation index (ODI) was 22.3 ± 25.99 among subjects with OSA. Sleep apnea related with rapid eye movement was present in 40% of OSA subjects. AHI and ODI were higher among sarcoidosis subjects with parenchymal involvement (P = 0.019, P = 0.026). OSA frequency was higher in the group with parenchymal involvement, but the difference was not statistically significant (n = 10/15, %66 vs n = 5/14, %35). FEV1 and FVC were not related with AHI and ODI. CONCLUSION: We found a high rate of OSA in sarcoidosis. There was a trend of high OSA frequency in sarcoidosis subjects with parenchymal involvement.


Asunto(s)
Sarcoidosis Pulmonar/complicaciones , Sarcoidosis Pulmonar/patología , Apnea Obstructiva del Sueño/epidemiología , Adulto , Análisis de los Gases de la Sangre , Índice de Masa Corporal , Estudios Transversales , Femenino , Volumen Espiratorio Forzado , Humanos , Masculino , Persona de Mediana Edad , Polisomnografía , Factores de Riesgo , Sarcoidosis Pulmonar/fisiopatología , Apnea Obstructiva del Sueño/diagnóstico , Apnea Obstructiva del Sueño/fisiopatología , Capacidad Vital
12.
Forsch Komplementmed ; 21(4): 239-45, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-25231565

RESUMEN

BACKGROUND: Since the 1970s, MORA bioresonance therapy has globally been applied in the context of complementary medicine for various indications. In this regard, practitioners also report successful application in smoking cessation. The present study aims to verify these reports in a controlled study setting. METHODS: In order to achieve the aforementioned objective, we subjected the bioresonance method to a prospective, placebo-controlled, double-blind, parallel-group study involving 190 smokers. In both study groups (placebo n = 95; active bioresonance group; n = 95) the course of treatment and study conditions were standardized. RESULTS: 1 week (77.2% vs. 54.8%), 2 weeks (62.4% vs. 34.4%), 1 month (51.1% vs. 28.6%), and 1 year (28.6% vs. 16.1%) after treatment, the success rate in the verum group differed significantly from the results in the placebo group. Also, the subjective health condition after treatment and subjective assessment of efficacy, polled after 1 week, were significantly more positive among participants in the active bioresonance therapy group than among those in the placebo group. Adverse side effects were not observed. CONCLUSION: According to the findings attained by this pilot study, bioresonance therapy is clinically effective in smoking cessation and does not show any adverse side effects.


Asunto(s)
Terapias Complementarias/normas , Cese del Hábito de Fumar/métodos , Adolescente , Adulto , Anciano , Método Doble Ciego , Femenino , Humanos , Masculino , Persona de Mediana Edad , Proyectos Piloto , Encuestas y Cuestionarios , Resultado del Tratamiento , Turquía , Adulto Joven
13.
Sleep Breath ; 17(4): 1281-8, 2013 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-23563999

RESUMEN

PURPOSE: The incidence of obstructive sleep apnea (OSA) in interstitial lung disease (ILD) has been reported at different frequencies in several studies. The aims of our study were to evaluate the frequency of OSA in ILD and to analyze the relationship between polysomnography (PSG) findings and pulmonary function, disease severity, parenchymal involvement, and Epworth Sleepiness Scale (ESS) scores. METHODS: ILD patients with parenchymal involvement were evaluated. The disease severity was assessed using an index consisting of body mass index (BMI), carbon monoxide diffusion capacity, the Modified Medical Research Council dyspnea scale, and the 6-min walking distance. All of the patients had lung function, chest X-ray, PSG, ESS scoring, and an upper airway examination. Patients with a BMI ≥ 30 or significant upper airway pathologies were excluded. RESULTS: Of 62 patients, 50 patients comprised the study group (14 male, 36 female; mean age 54 ± 12.35 years, mean BMI 25.9 ± 3.44 kg/m(2)) with diagnoses of idiopathic pulmonary fibrosis (IPF; n = 17), stage II-III sarcoidosis (n = 15), or scleroderma (n = 18). The frequency of OSA was 68 %. The mean apnea-hypopnea index (AHI) was 11.4 ± 12.5. OSA was more common in IPF patients (p = 0.009). The frequency of rapid eye movement-related sleep apnea was 52.9 %. The frequency of OSA was higher in patients with a disease severity index ≥3 (p = 0.04). The oxygen desaturation index and the AHI were higher in patients with diffuse radiological involvement (p = 0.007 and p = 0.043, respectively). CONCLUSIONS: OSA is common in ILD. PSG or at minimum nocturnal oximetry should be performed, particularly in patients with functionally and radiologically severe disease.


Asunto(s)
Enfermedades Pulmonares Intersticiales/diagnóstico , Enfermedades Pulmonares Intersticiales/epidemiología , Apnea Obstructiva del Sueño/diagnóstico , Apnea Obstructiva del Sueño/epidemiología , Adulto , Anciano , Análisis de los Gases de la Sangre , Comorbilidad , Estudios Transversales , Trastornos de Somnolencia Excesiva/diagnóstico , Trastornos de Somnolencia Excesiva/epidemiología , Femenino , Humanos , Incidencia , Masculino , Persona de Mediana Edad , Polisomnografía , Estudios Prospectivos , Espirometría , Encuestas y Cuestionarios , Turquía
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA